scholarly journals The role of 14-3-3 η as a biomarker in rheumatoid arthritis

2021 ◽  
Vol 2 (2) ◽  
pp. 87-90
Author(s):  
Dima Abdelhafiz ◽  
Sally Kilborn ◽  
Marwan Bukhari
Keyword(s):  
Rheumatoid Arthritis ◽  
Response To Treatment ◽  
Inflammatory Disorder ◽  
C Reactive Protein ◽  
Prognostic Information ◽  
Reactive Protein ◽  
Appropriate Treatment ◽  
Good Disease Control ◽  
Novel Biomarkers

Abstract Rheumatoid arthritis (RA) is a chronic multisystem inflammatory disorder with significant morbidity and mortality. Making an early diagnosis and providing appropriate treatment decisions based on clinical and other parameter results in good disease control. Biomarkers, such as C reactive protein (CRP), anti-cyclic citrullinated peptides (anti-CCP), and erythrocyte sedimentation rate (ESR), have been traditionally used. Recently novel biomarkers are described. This article reviews the evidence behind a novel biomarker 14-3-3 η that has been found to provide additional diagnostic and prognostic information as well as predicting response to treatment. A systematic literature review is presented showing the evidence behind this molecule.

Role of high sensitivity C - Reactive protein and some of heavy metals in patients with rheumatoid arthritis

2020 ◽  
Vol 23 (16) ◽  
Author(s):  
Nashwan S. Albabawaty ◽  
Ali Y. Majid ◽  
Mohammed H. Alosami ◽  
Halla G. Mahmood
Keyword(s):  
Rheumatoid Arthritis ◽  
Heavy Metals ◽  
High Sensitivity ◽  
C Reactive Protein ◽  
Reactive Protein

Study of serum adenosine deaminase activity and c-reactive protein in patients of rheumatoid arthritis

2020 ◽  
Vol 11 (4) ◽  
pp. 7990-7993
Author(s):  
Sangeetha R ◽  
Ramesh Raju K A P ◽  
Hemapriya S ◽  
Suganthi V ◽  
Panneerselvam P
Keyword(s):  
Rheumatoid Arthritis ◽  
Adenosine Deaminase ◽  
Treatment Plan ◽  
Colorimetric Method ◽  
Disease Score ◽  
C Reactive Protein ◽  
Positive Correlation ◽  
Reactive Protein ◽  
Adenosine Deaminase Activity

Rheumatoid arthritis (RA) is a chronic disease that causes inflammatory synovitis. The treatment plan of RA includes reducing inflammation and improving the quality of life. Hence, understanding the role of Adenosine deaminase (ADA) and C-reactive protein helps for a better plan of treatment. The present study was undertaken to determine the serum ADA activity and CRP in RA patients and correlate with the severity of the progression of the disease. 25 patients diagnosed with RA as per 2010 ACR/EULAR criteria and 25 age and sex matched healthy controls were included in the study after informed consent. Blood samples were collected from all the subjects after an overnight fast, serum separated was analyzed immediately for Adenosine deaminase(ADA) activity measured using colorimetric method of Guisti and Galanti. Disease score, C-reactive protein, RA factor, ADA and ESR were significantly higher in cases when compared with controls. Significant positive correlation was present between the disease score and C-reactive protein, RA factor among cases. A positive correlation was observed between the disease score and ADA, but it was not statistically significant among cases.

scholarly journals Addressing the Perfect Storm: Biomarkers in Obesity and Pathophysiology of Cardiometabolic Risk

2018 ◽  
Vol 64 (1) ◽  
pp. 142-153 ◽  
Author(s):  
Krasimira Aleksandrova ◽  
Dariush Mozaffarian ◽  
Tobias Pischon
Keyword(s):  
Risk Factors ◽  
Disease Prediction ◽  
C Reactive Protein ◽  
Disease Etiology ◽  
Fatty Acid Binding ◽  
Therapeutic Implications ◽  
Cardiometabolic Diseases ◽  
Reactive Protein ◽  
Novel Biomarkers

AbstractBACKGROUNDThe worldwide rise of obesity has provoked intensified research to better understand its pathophysiology as a means for disease prevention. Several biomarkers that may reflect various pathophysiological pathways that link obesity and cardiometabolic diseases have been identified over the past decades.CONTENTWe summarize research evidence regarding the role of established and novel obesity-related biomarkers, focusing on recent epidemiological evidence for detrimental associations with cardiometabolic diseases including obesity-related cancer. The reviewed biomarkers include biomarkers of glucose–insulin homeostasis (insulin, insulin-like growth factors, and C-peptide), adipose tissue biomarkers (adiponectin, omentin, apelin, leptin, resistin, and fatty-acid-binding protein-4), inflammatory biomarkers (C-reactive protein, interleukin 6, tumor necrosis factor α), and omics-based biomarkers (metabolites and microRNAs).SUMMARYAlthough the evidence for many classical obesity biomarkers, including adiponectin and C-reactive protein (CRP), in disease etiology has been initially promising, the evidence for a causal role in humans remains limited. Further, there has been little demonstrated ability to improve disease prediction beyond classical risk factors. In the era of “precision medicine,” there is an increasing interest in novel biomarkers, and the extended list of potentially promising biomarkers, such as adipokines, cytokines, metabolites, and microRNAs, implicated in obesity may bring new promise for improved, personalized prevention. To further evaluate the role of obesity-related biomarkers as etiological and early-disease-prediction targets, well-designed studies are needed to evaluate temporal associations, replicate findings, and test clinical utility of novel biomarkers. In particular, studies to determine the therapeutic implications of novel biomarkers beyond established metabolic risk factors are highly warranted.

scholarly journals The role of laboratory biomarkers in monitoring of rituximab biosimilar therapy (Acellbia, “BIOCAD”) in patients with rheumatoid arthritis

2019 ◽  
Vol 91 (5) ◽  
pp. 26-33
Author(s):  
A S Avdeeva ◽  
M V Cherkasova ◽  
D A Kusevich ◽  
V V Rybakova ◽  
A S Artyuhov ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Total Dose ◽  
Erythrocyte Sedimentation Rate ◽  
Sedimentation Rate ◽  
Disease Duration ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
Erythrocyte Sedimentation ◽  
Laboratory Biomarkers

Aim: to evaluate the role of laboratory biomarkers in monitoring effectiveness of rituximab (RTM) biosimilar therapy in a total dose of 1200 mg. Materials and methods. 20 patients (pts) with rheumatoid arthritis (RA) (18 woman, mean age 61.5(54-66.5) years, mean disease duration 39.5(20-84) months, mean DAS28 5.6(4.9-6.8)) received two intravenous RTM biosimilar infusions (600 mg №2) in combination with DMARDs and glucocorticoids. Laboratory biomarkers were assessed at baseline and weeks 12 and 24 after the first infusion of RTX. Results. RTM biosimilar induced decreases in DAS28, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) at week 12 and 24, p

SAT0046 Role of C-Reactive Protein in Osteoclastogenesis in Rheumatoid Arthritis

2015 ◽  
Vol 74 (Suppl 2) ◽  
pp. 664.3-665
Author(s):  
H.-R. Kim ◽  
S.-H. Lee ◽  
S.-H. Lee ◽  
H.-Y. Kim
Keyword(s):  
Rheumatoid Arthritis ◽  
C Reactive Protein ◽  
Reactive Protein

scholarly journals Connective tissue remodelling is differently modulated by tocilizumab versus methotrexate monotherapy in patients with early rheumatoid arthritis: the AMBITION study

2021 ◽  
Vol 23 (1) ◽  
Author(s):  
Patryk J. Drobinski ◽  
Anne C. Bay-Jensen ◽  
Morten A. Karsdal ◽  
Samra Sardar ◽  
Anne S. Siebuhr
Keyword(s):  
Rheumatoid Arthritis ◽  
Active Rheumatoid Arthritis ◽  
Early Time ◽  
Response To Treatment ◽  
C Reactive Protein ◽  
Tissue Remodelling ◽  
Reactive Protein ◽  
Effect Of Treatment ◽  
And Gender ◽  
Spearman’S Correlation

Abstract Objective Associations between rheumatoid arthritis (RA) and effect of treatment at the tissue levels are poorly understood. We investigated the scope of released extracellular matrix (ECM) metabolites as a consequence of tissue remodelling in patients treated with methotrexate (MTX) and tocilizumab (TCZ) compared to placebo. Methods Tissue metabolites from 387 RA patients treated with either TCZ (8 mg/kg) or MTX monotherapy (7.5–20 mg/kg) were measured at baseline and 8 weeks sera by validated ELISA assays. The levels of collagen biomarkers (C1M, C2M, C3M and C4M) together with C-reactive protein (CRP) and CRP metabolite (CRPM) were investigated. Baseline levels of biomarkers have been compared with 72 age- and gender-matched healthy controls. Comparison between treatment and response groups were done by ANCOVA, Spearman’s correlation and logistic regression adjusted for age, gender, BMI and disease duration. Results C1M and C3M were significantly (P < 0.05) inhibited by TCZ and C3M by MTX (P < 0.01) compared to placebo. C1M and C3M inhibition with TCZ was respectively 23% and 16% greater than that of MTX (P < 0.01 and P < 0.0001). C4M was inhibited by TCZ and MTX, but the effect of TCZ was 22% greater than MTX (P < 0.0001). TCZ and MTX had minimal effect on C2M levels. MTX had no effect on CRP and CRPM, whereas TCZ reduced their levels to 69% and 27% from baseline. Investigated biomarkers revealed a significant (P < 0.05) difference in biomarker profiles of MTX ACR50 treatment responders and non-responders. Change to week 8 in levels of C3M, C4M, CRP and CRPM in MTX patients correlated significantly (rho = 0.41 to 0.18, P < 0.0001 to 0.039) with change in disease activity (DAS28) at weeks 8, 16 and 24, whereas only CRP in TCZ patients (rho = 0.32 to 0.21, P < 0.0001 to 0.01). Conclusion Patients receiving TCZ treatment for 8 weeks had higher suppression of tissue remodelling and inflammatory biomarkers over patients treated with MTX. Measured biomarkers enabled for a discrimination of biomarker profiles of ACR50 treatment responding patients and identification of those who benefit at the early time point. Week 8 change in levels of C3M, C4M, CRP and CRPM significantly predicted clinical response to treatment and correlated with DAS28 at all time points. Trial registration ClinicalTrials.gov, NCT00109408. Date of registration: July 2005. Name of the registry: A Study to Assess the Safety and Efficacy of Tocilizumab in Patients with Active Rheumatoid Arthritis.

scholarly journals Morphofunctional properties of platelets in patients with rheumatoid arthritis

2021 ◽  
pp. 55-61
Author(s):  
Z. V. Zubkova ◽  
I. A. Novikova
Keyword(s):  
Rheumatoid Arthritis ◽  
Platelet Count ◽  
Disease Activity ◽  
Peripheral Blood ◽  
Maximum Degree ◽  
Inflammatory Process ◽  
C Reactive Protein ◽  
Platelet Activity ◽  
Reactive Protein

Objective: to assess the morphofunctional properties of platelets in patients with rheumatoid arthritis (RA) in combination with other clinical and laboratory characteristics of the disease.Materials and methods. The parameters of platelet hemostasis were studied in 51 RA patients with varying degrees of disease activity according to the DAS28 index.Results. It has been found that the count of platelets in the peripheral blood and their aggregation properties depend on the indicators of the activity of the inflammatory process (degree of activity, ESR, level of C-reactive protein). Platelet indices (MPV, P-LCR, PDW) are interrelated with the relative counts of lymphocytes and segmented neutrophils in the peripheral blood. In RA patients who are seropositive for rheumatoid factor, its titer is associated with the morphofunctional properties of platelets (platelet count, MPV, maximum degree of aggregation in the ADP test).Conclusion. The role of platelets in the RA pathogenesis is not limited exclusively to the hemostatic function. The associations we identified between the platelet activity and the clinical and laboratory characteristics of the disease are indicative of their active participation in immunological processes.

scholarly journals Decrease in Serum Interleukin-21 Levels Is Associated With Disease Activity Improvement in Patients With Recent-Onset Rheumatoid Arthritis

2014 ◽  
pp. 475-481 ◽  
Author(s):  
O. SGLUNDA ◽  
H. F. MANN ◽  
H. HULEJOVÁ ◽  
O. PECHA ◽  
L. PLEŠTILOVÁ ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Disease Activity ◽  
Disease Activity Score ◽  
Serum Levels ◽  
Response To Treatment ◽  
Healthy Individuals ◽  
C Reactive Protein ◽  
Recent Onset ◽  
Reactive Protein ◽  
Interleukin 21

Interleukin-21 (IL-21) plays an important role in the pathogenesis of rheumatoid arthritis (RA). The aim of our study was to assess serum levels of IL-21 in patients with recent-onset RA in relation to disease activity and response to treatment. We analyzed serum levels of IL-21 in 51 RA patients, both before and 12 weeks after the initiation of treatment and in 36 healthy individuals. Disease activity was assessed at baseline and at weeks 12 and 24 using the Disease Activity Score for 28 joints, serum levels of C-reactive protein, and the total swollen joint count. We found that IL-21 levels were not increased in patients with recent-onset RA compared with healthy controls, but they had significantly decreased from baseline to week 12 during treatment. Baseline levels of IL-21 significantly correlated with measures of disease activity (p<0.02 for all). Although IL-21 levels did not predict achievement of remission, decrease in IL-21 levels correlated with improvement in disease activity after 12 weeks (p<0.02) and also after 24 weeks (p<0.04) of treatment. Our data suggest that circulating IL-21 levels may serve as a biomarker of disease activity and better outcome in early phase of RA.

scholarly journals Inflammatory response in rheumatoid arthritis

2004 ◽  
Vol 23 (4) ◽  
pp. 375-380 ◽  
Author(s):  
Ljiljana Petrovic-Rackov ◽  
Nada Pejnovic ◽  
Zoran Mijuskovic ◽  
Gordana Ercegovic
Keyword(s):  
Rheumatoid Arthritis ◽  
Synovial Fluid ◽  
Inflammatory Response ◽  
Tnf Alpha ◽  
C Reactive Protein ◽  
General Activity ◽  
Reactive Protein ◽  
High Degree ◽  
Active Disease

The aim of the research is to determine the clinical significance of cytokines TNF-alpha, IL-12, IL-15 and IL-18 in evaluation of the activity of rheumatoid arthritis (RA). By comparing the concentrations in 30 patients with high, 14 patients with moderate and 20 patients with mild activity of RA it is established that the patients with high degree of disease activity, have significantly high (p<0.01; p<0.05) concentrations of examined cytokines and rheumatoid factor in blood and synovial fluid as well as C-reactive protein in serum in relation to patients with moderate and mild active disease. We have concluded that the cytokines concentrations can be good indicators of the degree of the general activity of RA. This research can contribute to interpretation of insufficiently well known views of pathogenesis role of cytokines in active disease.

scholarly journals Prognosis of pneumonia in patients with rheumatoid arthritis: the role of medication and disease activity prior to admission a population-based cohort study

RMD Open ◽  
2020 ◽  
Vol 6 (1) ◽  
pp. e001102 ◽  
Author(s):  
Mette Holland-Fischer ◽  
Reimar W Thomsen ◽  
Ulrik Tarp ◽  
Mette Nørgaard
Keyword(s):  
Rheumatoid Arthritis ◽  
Cohort Study ◽  
Disease Activity ◽  
Population Based ◽  
C Reactive Protein ◽  
Subsequent Infection ◽  
Reactive Protein ◽  
Increased Risk ◽  
First Time

ObjectivePatients with rheumatoid arthritis (RA) experience an increased risk of infections, but the prognosis of infections is unclear. We examined if patients with RA have worse outcomes from pneumonia than non-RA individuals.MethodsIn a population-based cohort study, we computed 90-day mortality rates and crude and adjusted HRs comparing pneumonia patients with and without RA. Among patients with RA, we evaluated prognostic effects of RA medications including prednisolone and disease activity as assessed by C reactive protein (CRP) or platelet levels measured 30–180 days before admission to avoid any influence from the subsequent infection.ResultsAmong 52 577 patients hospitalised for the first time with pneumonia, 1220 (2.3%) had RA. The 90-day mortality was 19.9% for patients with RA and 18.9% for non-RA patients (adjusted 90-day HR of 1.05 (95% CI 0.92 to 1.19)). Compared with CRP levels <8 mg/L, CRP levels ≥20 mg/L predicted increased mortality in patients with RA with adjusted 90-day HRs of 4.98 (95% CI 2.19 to 11.36). Compared with methotrexate monotherapy, both prednisolone (HR 1.43 (95% CI 0.91 to 2.22)) and no RA therapy (HR 1.35 (95% CI 0.85 to 2.14)) tended to increase 90-day mortality. Compared with patients who used prednisolone and had low CRP levels, high CRP predicted increased mortality both in patients who used prednisolone (HR 3.09, 95% CI 1.25 to 7.65) and those who did not (HR 2.35, 95% CI 0.94 to 5.87).ConclusionsOverall, RA does not increase mortality following hospitalisation for pneumonia. However, high RA disease activity prior to admission predicts increased pneumonia mortality in patients regardless of prednisolone use.

Sign in / Sign up

Export Citation Format

Share Document